#Baricitinib in refractory #myositis? A ‘weak’ trial design comparing #Bari to #Bari Rx started 12 weeks later in a small N =15 neat idea but NO answer 👇 looked like 👍 it worked BUT this is not the #RCT design that can show differences #ACR24 @RheumNow abst#1731 @ACRheum